Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04281498
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
- NCT04281498 ↗
- Completed
- John Mascarenhas
- Focused
We haven't built an HCP commentary report on NCT04281498 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04281498 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Accelerated/Blast-phase Myeloproliferative Neoplasm; Chronic-phase Myelofibrosis; IDH2 Mutation
- Interventions
- Ruxolitinib; Enasidenib
- Arms
- Patients with MPN · Experimental
- Enrollment
- 6
- Primary outcomes
- Number of MPN Participants With Response
- Sponsor
- John Mascarenhas with Celgene Corporation, Incyte Corporation, Myeloproliferative Neoplasms Research Consortium, National Institutes of Health (NIH), National Cancer Institute (NCI)
- Start
- Jan 14, 2021
- Primary completion
- May 30, 2023
- Results posted
- Yes
- Registry record
- NCT04281498 · updated Feb 4, 2025